High Expression COL10A1 Promotes Breast Cancer Progression and Predicts Poor Prognosis

Overview

Journal Heliyon

Specialty Social Sciences

Date 2022 Oct 25

PMID 36281404

Authors

Weijian Zhou

Yuting Li

Dingyi Gu

Junying Xu

Runjie Wang

Huiyu Wang

Chaoying Liu

Affiliations

Soon will be listed here.

Abstract

Background: As a common malignant disease in females, breast cancer (BCa) causes increasing numbers of cancer-related death. Collagen X alpha 1 chain (COL10A1) plays a critical role in the oncogenesis and progression of malignant tumors. However, a systematic analysis of COL10A1 in BCa has not been conducted.

Methods: The COL10A1 expression level and prognostic value in BCa were defined through the Cancer Genome Atlas (TCGA) as well as the Kaplan-Meier plotter data respectively. The expression pattern of COL10A1 was subsequently confirmed on tissue microarray (TMA) by immunochemistry (IHC) staining. Moreover, cellular functional assays which aimed to evaluate cell proliferation, migration, invasion, and apoptosis, were conducted to investigate the oncogenic activity of COL10A1 in BCa. Then, Tumor Immune Estimation Resource (TIMER) was adopted to determine the association between COL10A1 expression and immune cell infiltration.

Results: Bioinformatics analysis revealed that COL10A1 was significantly overexpressed and had notable prognostic value, especially for distant metastasis-free survival (DMFS) in BCa. Moreover, IHC analysis of 140 BCa tissues on TMA chips exhibited the overexpression of COL10A1 was correlated to advanced clinical stage, poor overall survival (OS), and worse recurrence-free survival (RFS). Besides, knockdown of COL10A1 remarkably suppressed cell proliferation, migration, and invasion in BCa cells, and notably promoted cell apoptosis as well. Furthermore, COL10A1 was positively associated with immune cell infiltration including B cell, CD8 T cell, CD4 T cell, macrophage, neutrophil, and dendritic cell.

Conclusion: The results revealed that COL10A1 is a novel oncogene and could serve as a potential prognostic biomarker in BCa. Besides, the downregulation of COL10A1 could inhibit BCa progression, which could be a potential target for BCa therapy.

Citing Articles

Breast cancer prediction based on gene expression data using interpretable machine learning techniques.

Kallah-Dagadu G, Mohammed M, Nasejje J, Mchunu N, Twabi H, Batidzirai J Sci Rep. 2025; 15(1):7594.

PMID: 40038307 PMC: 11880515. DOI: 10.1038/s41598-025-85323-5.

Heterogeneous Clustering of Multiomics Data for Breast Cancer Subgroup Classification and Detection.

Pateras J, Lodi M, Rana P, Ghosh P Int J Mol Sci. 2025; 26(4).

PMID: 40004168 PMC: 11855380. DOI: 10.3390/ijms26041707.

Advances in the study of disulfidptosis in digestive tract tumors.

Chen Y, Zhang D, Yang H, Wu J, He W Discov Oncol. 2025; 16(1):186.

PMID: 39954025 PMC: 11829889. DOI: 10.1007/s12672-025-01875-y.

From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment.

Hulahan T, Angel P J Exp Clin Cancer Res. 2024; 43(1):329.

PMID: 39716322 PMC: 11664872. DOI: 10.1186/s13046-024-03236-z.

COL10A1 Facilitates Prostate Cancer Progression by Interacting With INHBA to Activate the PI3K/AKT Pathway.

Jiang K, Xu L, Cheng F, Ning J J Cell Mol Med. 2024; 28(23):e70249.

PMID: 39656597 PMC: 11629901. DOI: 10.1111/jcmm.70249.

References

Liang Y, Xia W, Zhang T, Chen B, Wang H, Song X . Upregulated Collagen COL10A1 Remodels the Extracellular Matrix and Promotes Malignant Progression in Lung Adenocarcinoma. Front Oncol. 2020; 10:573534. PMC: 7726267. DOI: 10.3389/fonc.2020.573534. View

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Huang H, Li T, Ye G, Zhao L, Zhang Z, Mo D . High expression of COL10A1 is associated with poor prognosis in colorectal cancer. Onco Targets Ther. 2018; 11:1571-1581. PMC: 5865565. DOI: 10.2147/OTT.S160196. View

Li Y, Wang X, Shi L, Xu J, Sun B . Predictions for high and expression resulting in a poor prognosis in esophageal squamous cell carcinoma by bioinformatics analyses. Transl Cancer Res. 2022; 9(1):85-94. PMC: 8798449. DOI: 10.21037/tcr.2019.11.11. View

Guo Q, Zheng M, Xu Y, Wang N, Zhao W . MiR-384 induces apoptosis and autophagy of non-small cell lung cancer cells through the negative regulation of Collagen α-1(X) chain gene. Biosci Rep. 2018; 39(2). PMC: 6356039. DOI: 10.1042/BSR20181523. View

Zhang T, Tan X, Xu Y, Wang Z, Xiao C, Liu R . Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer. Chin Med J (Engl). 2017; 130(6):710-716. PMC: 5358422. DOI: 10.4103/0366-6999.201613. View

Yu L, Tang J, Zhang C, Zeng W, Yan H, Li M . New Immunotherapy Strategies in Breast Cancer. Int J Environ Res Public Health. 2017; 14(1). PMC: 5295319. DOI: 10.3390/ijerph14010068. View

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View

Schmid T, Conrad H . A unique low molecular weight collagen secreted by cultured chick embryo chondrocytes. J Biol Chem. 1982; 257(20):12444-50. View

10.

Chung K, Jacenko O, Boyle P, Olsen B, Nishimura I . Craniofacial abnormalities in mice carrying a dominant interference mutation in type X collagen. Dev Dyn. 1997; 208(4):544-52. DOI: 10.1002/(SICI)1097-0177(199704)208:4<544::AID-AJA10>3.0.CO;2-X. View

11.

Provenzano E, Ulaner G, Chin S . Molecular Classification of Breast Cancer. PET Clin. 2018; 13(3):325-338. DOI: 10.1016/j.cpet.2018.02.004. View

12.

Esteva F, Hubbard-Lucey V, Tang J, Pusztai L . Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019; 20(3):e175-e186. DOI: 10.1016/S1470-2045(19)30026-9. View

13.

Page D, Bear H, Prabhakaran S, Gatti-Mays M, Thomas A, Cobain E . Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019; 5:34. PMC: 6783471. DOI: 10.1038/s41523-019-0130-x. View

14.

Jacenko O, LuValle P, Olsen B . Spondylometaphyseal dysplasia in mice carrying a dominant negative mutation in a matrix protein specific for cartilage-to-bone transition. Nature. 1993; 365(6441):56-61. DOI: 10.1038/365056a0. View

15.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

16.

Chen S, Wei Y, Liu H, Gong Y, Zhou Y, Yang H . Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics. Bioengineered. 2020; 12(1):127-137. PMC: 8291830. DOI: 10.1080/21655979.2020.1864912. View

17.

Chen Q, Gibney E, Fitch J, Linsenmayer C, Schmid T, Linsenmayer T . Long-range movement and fibril association of type X collagen within embryonic cartilage matrix. Proc Natl Acad Sci U S A. 1990; 87(20):8046-50. PMC: 54889. DOI: 10.1073/pnas.87.20.8046. View

18.

Gyorffy B, Lanczky A, Eklund A, Denkert C, Budczies J, Li Q . An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2009; 123(3):725-31. DOI: 10.1007/s10549-009-0674-9. View

19.

Li J, Wang X, Zheng K, Liu Y, Li J, Wang S . The clinical significance of collagen family gene expression in esophageal squamous cell carcinoma. PeerJ. 2019; 7:e7705. PMC: 6779144. DOI: 10.7717/peerj.7705. View

20.

Makoukji J, Makhoul N, Khalil M, El-Sitt S, Saad Aldin E, Jabbour M . Gene expression profiling of breast cancer in Lebanese women. Sci Rep. 2016; 6:36639. PMC: 5114572. DOI: 10.1038/srep36639. View